Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 1998, p. 2174-2177, Vol. 42, No. 9
Department of Clinical Pharmacology, Huddinge
Hospital, SE-14186, Huddinge, Sweden
Received 18 February 1997/Returned for modification 11 November
1997/Accepted 10 June 1998
Microdialysis was applied to sample the unbound drug concentration
in the extracellular fluid in brain and muscle of rats given
zalcitabine (2',3'-dideoxycytidine; n = 4) or BEA005
(2',3'-dideoxy-3'-hydroxymethylcytidine; n = 4) (50 mg/kg of body weight given subcutaneously). Zalcitabine and BEA005 were
analyzed by high-pressure liquid chromatography with UV detection. The
maximum concentration of zalcitabine in the dialysate
(Cmax) was 31.4 ± 5.1 µM (mean ± standard error of the mean) for the brain and 238.3 ± 48.1 µM
for muscle. The time to Cmax was found to be
from 30 to 45 min for the brain and from 15 to 30 min for muscle.
Zalcitabine was eliminated from the brain and muscle with half-lives
1.28 ± 0.64 and 0.85 ± 0.13 h, respectively. The ratio
of the area under the concentration-time curve (AUC) (from 0 to 180 min) for the brain and the AUC for muscle (AUC ratio) was 0.191 ± 0.037. The concentrations of BEA005 attained in the brain and muscle
were lower than those of zalcitabine, with
Cmaxs of 5.7 ± 1.4 µM in the brain and
61.3 ± 12.0 µM in the muscle. The peak concentration in the
brain was attained 50 to 70 min after injection, and that in muscle was
achieved 30 to 50 min after injection. The half-lives of BEA005 in the
brain and muscle were 5.51 ± 1.45 and 0.64 ± 0.06 h,
respectively. The AUC ratio (from 0 to 180 min) between brain and
muscle was 0.162 ± 0.026. The log octanol/water partition
coefficients were found to be
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Pharmacokinetics and Distribution over the
Blood-Brain Barrier of Zalcitabine (2',3'-Dideoxycytidine) and
BEA005 (2',3'-Dideoxy-3'-Hydroxymethylcytidine) in Rats,
Studied by Microdialysis
1.19 ± 0.04 and
1.47 ± 0.01 for zalcitabine and BEA005, respectively. The degrees of plasma
protein binding of zalcitabine (11% ± 4%) and BEA005 (18% ± 2%)
were measured by microdialysis in vitro. The differences between
zalcitabine and BEA005 with respect to the AUC ratio
(P = 0.481), half-life in muscle (P = 0.279), and level of protein binding (P = 0.174) were
not statistically significant. The differences were statistically
significant in the case of the half-life in the brain
(P = 0.032), clearance (P = 0.046),
volume of distribution (P = 0.027) in muscle, and octanol/water partition coefficient (P = 0.019).
*
Corresponding author. Mailing address: Department of
Clinical Pharmacology, Huddinge Hospital, SE-14186, Huddinge,
Sweden. Phone: 46 858581068. Fax: 46 858581070. E-mail:
natalia.borg{at}pharmlab.hs.sll.se.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»